Colestyramine - Albireo

Drug Profile

Colestyramine - Albireo

Alternative Names: A 3384

Latest Information Update: 12 Jan 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Albireo AB
  • Developer Albireo AB; Albireo Pharma
  • Class Antidiarrhoeals; Antihyperlipidaemics
  • Mechanism of Action Bile acid binding protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Primary bile acid malabsorption
  • No development reported Intrahepatic cholestasis

Most Recent Events

  • 23 Nov 2016 No recent reports on development identified - Phase-I for Intrahepatic cholestasis (Combination therapy, In volunteers) in United Kingdom (PO)
  • 02 Aug 2016 Chemical structure information added
  • 28 Jul 2016 Albireo plans a clinical trial for Primary bile acid malabsorption (Albireo website, July 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top